SEARCH

SEARCH BY CITATION

References

  • 1
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 240516.
  • 2
    Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195206.
  • 3
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 143344.
  • 4
    McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 58093.
  • 5
    Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399401.
  • 6
    Estrabaud E, Vidaud M, Marcellin P, Asselah T. et al. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012; 57: 111025.
  • 7
    Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 1209.
  • 8
    Moreno C, Deltenre P, Pawlotsky JM, et al. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol 2010; 52: 2531.
  • 9
    Leroy V, Serfaty L, Bourlière M, et al. Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. Liver Intern 2012; 32: 147792.
  • 10
    Pearlman BL, Ehleben C. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin can be treated without a protease inhibitor, irrespective of IL28B status or patient ethnicity. Hepatology 2012; 56: 268A.
  • 11
    Pascale A, Chazouillères O, Serfaty L. Pegylated interferon and ribavirin: a therapeutic option in patients who fail to respond to telaprevir-based triple therapy? Hepatology 2013; 58: 828.
  • 12
    Lawitz E, Forns X, Zeuzem S, et al. Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients WHO Relapsed After Previous Interferon-Based Therapy: Results From Promise, a Phase III Trial. Digestive Disease Week. Orlando, May 18-21, 2013. Abstract 869b.
  • 13
    Ferenci P, Asselah T, Foster GR, et al. Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from STARTVerso1, a randomised double blind placebo-controlled phase III trial. 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013). Amsterdam, April 24-28, 2013. Abstract 1416.
  • 14
    Lawiitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 187887.
  • 15
    Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int 2013; 33(Suppl 1): 93104.